{"id":53569,"date":"2026-08-21T10:46:44","date_gmt":"2026-08-21T10:46:44","guid":{"rendered":"https:\/\/www.vtmarkets.com\/en-mena\/uncategorized\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/"},"modified":"2026-08-21T10:46:44","modified_gmt":"2026-08-21T10:46:44","slug":"moderna-merck-and-the-different-ways-markets-value-a-breakthrough","status":"publish","type":"post","link":"https:\/\/www.vtmarkets.com\/en-mena\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/","title":{"rendered":"Moderna, Merck and the Different Ways Markets Value a Breakthrough"},"content":{"rendered":"<figure class=\"wp-block-post-featured-image\"><img loading=\"lazy\" decoding=\"async\" width=\"1250\" height=\"700\" src=\"https:\/\/www.vtmarkets.com\/en-mena\/wp-content\/uploads\/sites\/7\/2026\/08\/Moderna-Merck-pharma.webp\" class=\"attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" style=\"object-fit:cover;\" srcset=\"https:\/\/www.vtmarkets.com\/en-mena\/wp-content\/uploads\/sites\/7\/2026\/08\/Moderna-Merck-pharma.webp 1250w, https:\/\/www.vtmarkets.com\/en-mena\/wp-content\/uploads\/sites\/7\/2026\/08\/Moderna-Merck-pharma-300x168.webp 300w, https:\/\/www.vtmarkets.com\/en-mena\/wp-content\/uploads\/sites\/7\/2026\/08\/Moderna-Merck-pharma-1024x573.webp 1024w, https:\/\/www.vtmarkets.com\/en-mena\/wp-content\/uploads\/sites\/7\/2026\/08\/Moderna-Merck-pharma-768x430.webp 768w, https:\/\/www.vtmarkets.com\/en-mena\/wp-content\/uploads\/sites\/7\/2026\/08\/Moderna-Merck-pharma-500x280.webp 500w, https:\/\/www.vtmarkets.com\/en-mena\/wp-content\/uploads\/sites\/7\/2026\/08\/Moderna-Merck-pharma-400x224.webp 400w, https:\/\/www.vtmarkets.com\/en-mena\/wp-content\/uploads\/sites\/7\/2026\/08\/Moderna-Merck-pharma-350x196.webp 350w, https:\/\/www.vtmarkets.com\/en-mena\/wp-content\/uploads\/sites\/7\/2026\/08\/Moderna-Merck-pharma-200x112.webp 200w\" sizes=\"auto, (max-width: 1250px) 100vw, 1250px\" \/><\/figure>\n\n\n<p class=\"wp-block-paragraph\">On Wednesday, 19 August, Moderna announced that its personalised mRNA cancer therapy had <a href=\"https:\/\/www.cnbc.com\/2026\/08\/19\/moderna-merck-cancer-vaccine-shows-initial-late-stage-melanoma-data.html\">succeeded in a Phase 3 trial<\/a>. The news sent the stock sharply higher. Shares rose 177%, <a href=\"https:\/\/www.wsj.com\/health\/pharma\/moderna-merck-vaccine-succeeds-in-preventing-melanoma-from-returning-540e9e18?mod=hp_lead_pos5\">more than doubling in a single session<\/a> and closing above $174. Merck, which partnered with Moderna on the programme, also gained, rising 12.6%.<\/p>\n\n\n\n<script type=\"module\" src=\"https:\/\/widgets.tradingview-widget.com\/w\/en\/tv-tickers.js\"><\/script>\n\n<tv-tickers symbols=\"NASDAQ:MRNA,NYSE:MRK\" hover-type=\"performance-grid\" show-hover><\/tv-tickers>\n\n\n\n<p class=\"wp-block-paragraph\">The reaction did not last equally for both companies. By Thursday afternoon, Moderna had fallen as much as 25%, trading near $129, and eventually closed down around 19%. Nearly <a href=\"https:\/\/www.forbes.com\/sites\/tylerroush\/2026\/08\/20\/moderna-stock-plunges-25-wiping-out-18-billion-after-historic-cancer-vaccine-breakthrough\/\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">$18 billion in market value disappeared from the stock<\/a>. Merck, meanwhile, ended the same session down just 0.57%.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The trial result itself had not changed. The same data that sent Moderna higher on Wednesday was still there on Thursday. The difference was how investors viewed each company&#8217;s ability to turn that scientific breakthrough into long-term value, defining the price gap between discovery and value.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What the trial showed<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Intismeran autogene is a personalised cancer therapy designed around the specific mutations found in an individual patient&#8217;s tumour. The treatment aims to train the immune system to recognise and attack those cancer targets.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">It is used alongside <a href=\"https:\/\/www.merck.com\/news\/keytruda-pembrolizumab-and-keytruda-qlex-pembrolizumab-and-berahyaluronidase-alfa-pmph-plus-paclitaxel-%C2%B1-bevacizumab-approved-for-certain-adults-with-pd-l1-cps-%E2%89%A51\/\">Merck&#8217;s Keytruda<\/a>, rather than as a replacement.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In the <a href=\"https:\/\/www.merck.com\/news\/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient\/\">INTerpath-001 trial<\/a>, the combination met its primary endpoint of recurrence-free survival and a secondary endpoint of distant metastasis-free survival in patients with stage IIB to IV melanoma after surgery.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The result marked the first positive late-stage trial for an mRNA-based cancer treatment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">However, one detail stood out. The announcement did not include hazard ratios or detailed efficacy figures. The market moved sharply based on a topline success announcement, before seeing the full data. That meant investors were not only pricing the science, they were also pricing the potential commercial impact.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Same breakthrough, different market value<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Moderna created the therapy and owns the underlying mRNA platform. Merck brought Keytruda, regulatory experience and global commercial reach.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Both companies benefited from the result, but investors viewed their opportunities differently.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>For Moderna, the trial created more possibilities. A successful personalised cancer vaccine platform could eventually expand across several cancer types.<\/li>\n\n\n\n<li>For Merck, the opportunity was more immediate. The treatment could potentially strengthen the Keytruda franchise<a href=\"https:\/\/www.businesstimes.com.sg\/international\/merck-create-separate-cancer-business-keytruda-patent-loss-looms\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\"> at a time when the company faces one of the biggest patent expiries in the pharmaceutical industry<\/a>.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The market was not only asking, &#8220;Who created the breakthrough?&#8221;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">It was asking, &#8220;Who is best positioned to monetise it?&#8221;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">MRK&#8217;s clearer path to commercial value<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Merck&#8217;s challenge is straightforward: replacing revenue from Keytruda before patent protection expires.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Keytruda <a href=\"https:\/\/finance.yahoo.com\/news\/keytruda-aid-mrks-growth-2026-144800572.html\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">generated around $25.3 billion in annual sales<\/a> and <a href=\"https:\/\/www.barrons.com\/articles\/keytruda-gardasil-sales-merck-stock-c19d0661\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">remains one of the world&#8217;s biggest medicines<\/a>. US exclusivity expires in December 2028, while government pricing measures under the Inflation Reduction Act begin affecting selected drugs from January 2028.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">That gives Merck a clear timeline.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A successful combination therapy using intismeran could help extend the commercial life of Keytruda. Instead of adding a completely separate product, Merck may be able to strengthen an existing treatment platform with a new generation of cancer care.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Investors reacted to that opportunity.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Morgan Stanley <a href=\"https:\/\/finance.yahoo.com\/markets\/stocks\/articles\/morgan-stanley-revamps-merck-stock-201857782.html\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">upgraded Merck to Overweight<\/a> and many <a href=\"https:\/\/www.gurufocus.com\/news\/9045774\/morgan-stanley-revamps-merck-stock-target-after-cancer-breakthrough?utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;r=caf6fe0e0db70d936033da5461e60141\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">analysts raised its price target<\/a>, arguing that pipeline assets including intismeran could help offset pressure from the Keytruda patent expiry.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Merck entered the announcement with a stronger financial base. Keytruda alone generated more than $16 billion in cash flow in the first half of 2026, giving the company greater flexibility to invest, develop and commercialise new treatments.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">MRNA needs to turn potential into revenue<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The situation looks different for Moderna.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The company owns a valuable platform, but it is still trying to prove that platform can generate sustainable earnings.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In the <a href=\"https:\/\/finance.yahoo.com\/healthcare\/articles\/moderna-q2-earnings-call-highlights-140404872.html\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">second quarter of 2026, Moderna reported<\/a> revenue of $145 million and a net loss of $782 million. Research and development expenses reached $651 million during the quarter, more than four times its revenue.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The company ended June with $6.9 billion in cash and investments, down from $7.5 billion three months earlier. Management expects year-end cash and investments of between $4.7 billion and $5.2 billion.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">At the same time, not every mRNA programme has progressed smoothly. Moderna&#8217;s <a href=\"https:\/\/www.bloomberg.com\/news\/articles\/2026-07-31\/moderna-says-early-results-of-norovirus-shot-were-not-successful\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">norovirus candidate mRNA-1403 failed to meet statistical criteria<\/a> in its Phase 3 interim analysis.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The cancer therapy result changed the company&#8217;s future possibilities, but it did not immediately change the underlying financial picture.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td class=\"has-text-align-center\" data-align=\"center\"><\/td><td class=\"has-text-align-center\" data-align=\"center\">Moderna<\/td><td class=\"has-text-align-center\" data-align=\"center\">Merck<\/td><\/tr><tr><td>Main contribution<\/td><td>mRNA platform and personalised therapy<\/td><td>Keytruda, commercial scale and distribution<\/td><\/tr><tr><td>Q2 2026 position<\/td><td>$145m revenue, $782m net loss<\/td><td>Keytruda generated over $16bn in H1 cash flow<\/td><\/tr><tr><td>Value of the data<\/td><td>Creates broader platform potential<\/td><td>Helps protect an existing revenue stream<\/td><\/tr><tr><td>Two-day stock move<\/td><td>+177%, then gave back around a fifth<\/td><td>+12.6%, largely held gains<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Moderna&#8217;s opportunity is based on optionality. The <a href=\"https:\/\/finance.yahoo.com\/healthcare\/articles\/moderna-shares-surge-more-90-132957599.html\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">company has nine Phase 2 and Phase 3 intismeran trials underway across melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma.<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">If the results translate across multiple cancers, the opportunity becomes significantly larger.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">However, optionality breeds uncertainty and harder for markets to value. A company with a promising platform but limited current earnings does not have the same financial anchor as a company with an established commercial product.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The patent cliff reshaping biotech<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Moderna-Merck partnership reflects <a href=\"https:\/\/finance.yahoo.com\/news\/big-pharma-navigating-300-billion-080000758.html\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">a broader trend across the pharmaceutical industry<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Around <a href=\"https:\/\/finance.yahoo.com\/news\/big-pharma-navigating-300-billion-080000758.html\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">$300 billion of branded pharmaceutical revenue is expected to face patent expiry pressure by 2030<\/a>. At the same time, biopharma deal activity has accelerated as larger companies look for replacement growth.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The reason is simple: established pharmaceutical companies are not only looking for new science. They are looking for new revenue streams before older ones decline.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">That changes the balance between biotech companies and large pharmaceutical firms.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Smaller companies often bring innovation and breakthrough science. Larger companies bring capital, regulatory experience and commercial infrastructure.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The value split between them is often decided long before the breakthrough arrives, when partnerships are first negotiated.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This is why scientific validation does not always mean the inventor captures the largest share of the value.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">BioNTech&#8217;s reaction showed another side of this dynamic. The company, which is developing its own personalised cancer vaccine programmes, fell 4% on the same day. Investors viewed the result as validation of the technology, but also as evidence of increasing competition.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The risks behind the optimism<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">All things given, the current market reaction may not tell the full story.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The biggest challenge is manufacturing. Personalised cancer therapies require every dose to be created for a specific patient. Scaling production, maintaining quality and managing logistics remain important questions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">If Moderna solves those challenges, its platform could become a meaningful competitive advantage.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pricing is another uncertainty. There is no established model for how health systems will reimburse personalised cancer treatments at scale. Strong clinical results do not automatically guarantee commercial success.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">There is also a longer-term argument in Moderna&#8217;s favour.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">If intismeran succeeds across additional cancer types, the value created could eventually be much larger than what investors are currently pricing in. The current difference between Moderna and Merck reflects today&#8217;s financial positions, not necessarily the final outcome.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What to watch next<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The scientific question has moved forward. The next debate is about execution and value capture.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Several factors will determine what happens next:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Results from additional trials, particularly in non-small cell lung cancer and bladder cancer, which could show whether the platform works beyond melanoma.<br><\/li>\n\n\n\n<li>Regulatory timelines and whether the companies can move quickly towards approval discussions.<br><\/li>\n\n\n\n<li>Moderna&#8217;s financial position, and whether future funding can be raised on stronger terms after this repricing.<br><\/li>\n\n\n\n<li>Future biotech-pharma partnerships, which may show whether innovators are gaining negotiating power.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Proving the science and capturing the economic value of that science are two different achievements. Merck&#8217;s gain held because the data had somewhere to go inside a business that already exists. Moderna&#8217;s didn&#8217;t, because that business is still being built.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\">One catalyst, two different setups. Moderna trades on event risk, moving hard on trial and regulatory news and drifting in between. Merck carries the same cancer treatment theme through a business already generating billions, which has so far meant smaller moves in both directions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Track live pricing and market reaction on both MRNA and MRK <a href=\"https:\/\/myaccount.vtmarkets.com\/login\/?utm_source=Opinion&amp;utm_content=ModernaMerckPharma\" target=\"_blank\" rel=\"noopener\" title=\"\">with VT Markets.<\/a><\/strong><\/p>\n\n\n\n<details class=\"wp-block-details is-layout-flow wp-block-details-is-layout-flow\"><summary>Tap for Trader&#8217;s Takeaway<\/summary>\n<p class=\"wp-block-paragraph\"><br><strong>What is the Moderna and Merck cancer vaccine partnership?<\/strong> <br>Moderna developed the personalised mRNA cancer therapy, while Merck provides Keytruda and commercial expertise. The partnership combines Moderna\u2019s technology with Merck\u2019s oncology capabilities.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Why did Moderna stock rise after its cancer vaccine trial result?<\/strong> <br>Moderna surged after its personalised mRNA cancer therapy achieved positive Phase 3 results, raising expectations for its future cancer pipeline.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Why did Merck stock benefit from Moderna\u2019s cancer breakthrough?<\/strong> <br>Merck\u2019s gain was linked to the potential for intismeran to strengthen Keytruda\u2019s franchise and help support future revenue growth.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Why did Moderna and Merck stocks react differently to the same breakthrough?<\/strong> <br>Moderna represents future platform potential, while Merck offers a clearer commercial path through an established oncology business.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>What does the Moderna and Merck stock split reveal about biotech breakthroughs?<\/strong> A successful therapy does not always create equal market value. Commercial scale, revenue visibility and timing can determine who benefits most.<\/p>\n<\/details>\n\r\n\n\n\n<p class=\"wp-block-paragraph\"><b>Start trading now \u2014 click <a href=\"https:\/\/www.vtmarkets.com\/en-mena\/trade-now\">here<\/a> to create your real VT Markets account.<\/b>\n\n<\/p>","protected":false},"excerpt":{"rendered":"<p>Moderna delivered the breakthrough, but Merck captured a different market reaction. The split shows how biotech value is created and captured.<\/p>\n","protected":false},"author":87,"featured_media":53568,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49],"tags":[],"class_list":["post-53569","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-opinion"],"acf":{"acf_article_selection_author":null},"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO Pro 5.0.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Moderna delivered the breakthrough, but Merck captured a different market reaction. The split shows how biotech value is created and captured.\" \/>\n\t<meta name=\"robots\" content=\"max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.vtmarkets.com\/en-mena\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO Pro (AIOSEO) 5.0.1\" \/>\n\n\t\t<script type=\"text\/javascript\"> (function(c,l,a,r,i,t,y){ c[a]=c[a]||function(){(c[a].q=c[a].q||[]).push(arguments)}; t=l.createElement(r);t.async=1;t.src=\"https:\/\/www.clarity.ms\/tag\/\"+i; y=l.getElementsByTagName(r)[0];y.parentNode.insertBefore(t,y); })(window, document, \"clarity\", \"script\", \"hvdc0bb30h\"); <\/script>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"VT Markets -\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Moderna, Merck and the Different Ways Markets Value a Breakthrough - VT Markets\" \/>\n\t\t<meta property=\"og:description\" content=\"Moderna delivered the breakthrough, but Merck captured a different market reaction. The split shows how biotech value is created and captured.\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.vtmarkets.com\/en-mena\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-08-21T10:46:44+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-08-21T10:46:44+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Moderna, Merck and the Different Ways Markets Value a Breakthrough - VT Markets\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Moderna delivered the breakthrough, but Merck captured a different market reaction. The split shows how biotech value is created and captured.\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#blogposting\",\"name\":\"Moderna, Merck and the Different Ways Markets Value a Breakthrough - VT Markets\",\"headline\":\"Moderna, Merck and the Different Ways Markets Value a Breakthrough\",\"author\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/author\\\/josephine\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/wp-content\\\/uploads\\\/sites\\\/7\\\/2026\\\/08\\\/Moderna-Merck-pharma.webp\",\"width\":1250,\"height\":700},\"datePublished\":\"2026-08-21T10:46:44+00:00\",\"dateModified\":\"2026-08-21T10:46:44+00:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#webpage\"},\"articleSection\":\"Opinion\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/category\\\/opinion\\\/#listItem\",\"name\":\"Opinion\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/category\\\/opinion\\\/#listItem\",\"position\":2,\"name\":\"Opinion\",\"item\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/category\\\/opinion\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#listItem\",\"name\":\"Moderna, Merck and the Different Ways Markets Value a Breakthrough\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#listItem\",\"position\":3,\"name\":\"Moderna, Merck and the Different Ways Markets Value a Breakthrough\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/category\\\/opinion\\\/#listItem\",\"name\":\"Opinion\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/#organization\",\"name\":\"VT Markets\",\"url\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/author\\\/josephine\\\/#author\",\"url\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/author\\\/josephine\\\/\",\"name\":\"josephine\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7809ddd0668c6cd297bde70914f1903a959aa8d1a194930855d6c5b37e53a6f0?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"josephine\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#webpage\",\"url\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/\",\"name\":\"Moderna, Merck and the Different Ways Markets Value a Breakthrough - VT Markets\",\"description\":\"Moderna delivered the breakthrough, but Merck captured a different market reaction. The split shows how biotech value is created and captured.\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/author\\\/josephine\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/author\\\/josephine\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/wp-content\\\/uploads\\\/sites\\\/7\\\/2026\\\/08\\\/Moderna-Merck-pharma.webp\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#mainImage\",\"width\":1250,\"height\":700},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/opinion\\\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\\\/#mainImage\"},\"datePublished\":\"2026-08-21T10:46:44+00:00\",\"dateModified\":\"2026-08-21T10:46:44+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/#website\",\"url\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/\",\"name\":\"VT Markets\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.vtmarkets.com\\\/en-mena\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO Pro -->\r\n\t\t<title>Moderna, Merck and the Different Ways Markets Value a Breakthrough - VT Markets<\/title>\n\n","aioseo_head_json":{"title":"Moderna, Merck and the Different Ways Markets Value a Breakthrough - VT Markets","description":"Moderna delivered the breakthrough, but Merck captured a different market reaction. The split shows how biotech value is created and captured.","canonical_url":"https:\/\/www.vtmarkets.com\/en-mena\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/","robots":"max-snippet:-1, max-image-preview:large, max-video-preview:-1","keywords":"","webmasterTools":{"miscellaneous":"&lt;script type=\"text\/javascript\"&gt; (function(c,l,a,r,i,t,y){ c[a]=c[a]||function(){(c[a].q=c[a].q||[]).push(arguments)}; t=l.createElement(r);t.async=1;t.src=\"https:\/\/www.clarity.ms\/tag\/\"+i; y=l.getElementsByTagName(r)[0];y.parentNode.insertBefore(t,y); })(window, document, \"clarity\", \"script\", \"hvdc0bb30h\"); &lt;\/script&gt;"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/www.vtmarkets.com\/en-mena\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#blogposting","name":"Moderna, Merck and the Different Ways Markets Value a Breakthrough - VT Markets","headline":"Moderna, Merck and the Different Ways Markets Value a Breakthrough","author":{"@id":"https:\/\/www.vtmarkets.com\/en-mena\/author\/josephine\/#author"},"publisher":{"@id":"https:\/\/www.vtmarkets.com\/en-mena\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/www.vtmarkets.com\/en-mena\/wp-content\/uploads\/sites\/7\/2026\/08\/Moderna-Merck-pharma.webp","width":1250,"height":700},"datePublished":"2026-08-21T10:46:44+00:00","dateModified":"2026-08-21T10:46:44+00:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/www.vtmarkets.com\/en-mena\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#webpage"},"isPartOf":{"@id":"https:\/\/www.vtmarkets.com\/en-mena\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#webpage"},"articleSection":"Opinion"},{"@type":"BreadcrumbList","@id":"https:\/\/www.vtmarkets.com\/en-mena\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.vtmarkets.com\/en-mena#listItem","position":1,"name":"Home","item":"https:\/\/www.vtmarkets.com\/en-mena","nextItem":{"@type":"ListItem","@id":"https:\/\/www.vtmarkets.com\/en-mena\/category\/opinion\/#listItem","name":"Opinion"}},{"@type":"ListItem","@id":"https:\/\/www.vtmarkets.com\/en-mena\/category\/opinion\/#listItem","position":2,"name":"Opinion","item":"https:\/\/www.vtmarkets.com\/en-mena\/category\/opinion\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.vtmarkets.com\/en-mena\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#listItem","name":"Moderna, Merck and the Different Ways Markets Value a Breakthrough"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.vtmarkets.com\/en-mena#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.vtmarkets.com\/en-mena\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#listItem","position":3,"name":"Moderna, Merck and the Different Ways Markets Value a Breakthrough","previousItem":{"@type":"ListItem","@id":"https:\/\/www.vtmarkets.com\/en-mena\/category\/opinion\/#listItem","name":"Opinion"}}]},{"@type":"Organization","@id":"https:\/\/www.vtmarkets.com\/en-mena\/#organization","name":"VT Markets","url":"https:\/\/www.vtmarkets.com\/en-mena\/"},{"@type":"Person","@id":"https:\/\/www.vtmarkets.com\/en-mena\/author\/josephine\/#author","url":"https:\/\/www.vtmarkets.com\/en-mena\/author\/josephine\/","name":"josephine","image":{"@type":"ImageObject","@id":"https:\/\/www.vtmarkets.com\/en-mena\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/7809ddd0668c6cd297bde70914f1903a959aa8d1a194930855d6c5b37e53a6f0?s=96&d=mm&r=g","width":96,"height":96,"caption":"josephine"}},{"@type":"WebPage","@id":"https:\/\/www.vtmarkets.com\/en-mena\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#webpage","url":"https:\/\/www.vtmarkets.com\/en-mena\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/","name":"Moderna, Merck and the Different Ways Markets Value a Breakthrough - VT Markets","description":"Moderna delivered the breakthrough, but Merck captured a different market reaction. The split shows how biotech value is created and captured.","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/www.vtmarkets.com\/en-mena\/#website"},"breadcrumb":{"@id":"https:\/\/www.vtmarkets.com\/en-mena\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#breadcrumblist"},"author":{"@id":"https:\/\/www.vtmarkets.com\/en-mena\/author\/josephine\/#author"},"creator":{"@id":"https:\/\/www.vtmarkets.com\/en-mena\/author\/josephine\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/www.vtmarkets.com\/en-mena\/wp-content\/uploads\/sites\/7\/2026\/08\/Moderna-Merck-pharma.webp","@id":"https:\/\/www.vtmarkets.com\/en-mena\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#mainImage","width":1250,"height":700},"primaryImageOfPage":{"@id":"https:\/\/www.vtmarkets.com\/en-mena\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/#mainImage"},"datePublished":"2026-08-21T10:46:44+00:00","dateModified":"2026-08-21T10:46:44+00:00"},{"@type":"WebSite","@id":"https:\/\/www.vtmarkets.com\/en-mena\/#website","url":"https:\/\/www.vtmarkets.com\/en-mena\/","name":"VT Markets","inLanguage":"en-US","publisher":{"@id":"https:\/\/www.vtmarkets.com\/en-mena\/#organization"}}]},"og:locale":"en_US","og:site_name":"VT Markets -","og:type":"article","og:title":"Moderna, Merck and the Different Ways Markets Value a Breakthrough - VT Markets","og:description":"Moderna delivered the breakthrough, but Merck captured a different market reaction. The split shows how biotech value is created and captured.","og:url":"https:\/\/www.vtmarkets.com\/en-mena\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/","article:published_time":"2026-08-21T10:46:44+00:00","article:modified_time":"2026-08-21T10:46:44+00:00","twitter:card":"summary_large_image","twitter:title":"Moderna, Merck and the Different Ways Markets Value a Breakthrough - VT Markets","twitter:description":"Moderna delivered the breakthrough, but Merck captured a different market reaction. The split shows how biotech value is created and captured."},"aioseo_meta_data":{"post_id":"53569","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"seo_analyzer_scan_date":"2026-08-21 10:47:03","breadcrumb_settings":null,"limit_modified_date":false,"open_ai":null,"created":"2026-08-21 10:46:44","updated":"2026-08-21 10:47:03","ai":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/www.vtmarkets.com\/en-mena\" title=\"Home\">Home<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t<a href=\"https:\/\/www.vtmarkets.com\/en-mena\/category\/opinion\/\" title=\"Opinion\">Opinion<\/a>\n<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\tModerna, Merck and the Different Ways Markets Value a Breakthrough\n<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.vtmarkets.com\/en-mena"},{"label":"Opinion","link":"https:\/\/www.vtmarkets.com\/en-mena\/category\/opinion\/"},{"label":"Moderna, Merck and the Different Ways Markets Value a Breakthrough","link":"https:\/\/www.vtmarkets.com\/en-mena\/opinion\/moderna-merck-and-the-different-ways-markets-value-a-breakthrough\/"}],"_links":{"self":[{"href":"https:\/\/www.vtmarkets.com\/en-mena\/wp-json\/wp\/v2\/posts\/53569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.vtmarkets.com\/en-mena\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.vtmarkets.com\/en-mena\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.vtmarkets.com\/en-mena\/wp-json\/wp\/v2\/users\/87"}],"replies":[{"embeddable":true,"href":"https:\/\/www.vtmarkets.com\/en-mena\/wp-json\/wp\/v2\/comments?post=53569"}],"version-history":[{"count":0,"href":"https:\/\/www.vtmarkets.com\/en-mena\/wp-json\/wp\/v2\/posts\/53569\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.vtmarkets.com\/en-mena\/wp-json\/wp\/v2\/media\/53568"}],"wp:attachment":[{"href":"https:\/\/www.vtmarkets.com\/en-mena\/wp-json\/wp\/v2\/media?parent=53569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.vtmarkets.com\/en-mena\/wp-json\/wp\/v2\/categories?post=53569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.vtmarkets.com\/en-mena\/wp-json\/wp\/v2\/tags?post=53569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}